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Acute hepatitis A is currently outbreaking in Korea. Although prognosis of acute hepatitis A is generally favorable, a minority of 
patients are accompanied by fatal complications. Severe cholestasis is one of the important causes of prolonged hospitalization 
in patients with acute hepatitis A. In such cases, higher chances of additional complications and increased medical costs are 
inevitable. We report three cases of severely cholestatic hepatitis A, who showed favorable responses to oral corticosteroids. 
Thirty milligram of prednisolone was initiated and tapered according to the responses. Rapid improvement was observed in all 
cases without side effects. We suggest that corticosteroid administration can be useful in hepatitis A patients with severe 
cholestasis who do not show improvement by conservative managements. Clinical trial will be needed to evaluate effectiveness of 
corticosteroids in these patients. (Korean J Hepatol 2010;16:329-333)
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INTRODUCTION
The incidence of acute viral hepatitis A is continuously 
increasing in Korea recently.
1 Patients present with fever, 
anorexia, nausea, vomiting, or jaundice, and frequently need 
hospitalization. The clinical course of acute hepatitis A is usually 
benign, and it is known that symptomatic treatment is sufficient 
for recovery.
2 However, in rare cases, acute hepatitis A can be 
associated with serious complications which require prolonged 
hospitalization, and may result in death or liver transplantation.
3 
Cholestatic hepatitis is one of atypical clinical manifestations of 
acute viral hepatitis. Although it occurs only at a rate of 
0.4~0.8%, protracted symptoms of anorexia, weight loss, 
pruritus, and jaundice are commonly associated.
3 These clinical 
situations prolong the length of hospital stay, which causes 
increased medical expenses and social costs.
It has been presented that there had been a rapid improvement 
of the clinical symptoms and signs in a patient with cholestatic 
hepatitis A after use of steroid.
4 However, there is no detailed 
information on the progress of the patient.
We recently experienced three cases of acute hepatitis A with 
severe cholestasis, whose serum bilirubin was promptly decreased 
following administration of steroid. Herein, we report our cases 
with detailed description of clinical courses and review of 
literatures.
CASE REPORT
Three patients were referred to Korea University Ansan 
Hospital for admission under the impression of acute hepatitis. 
The patients denied history of taking any medicines, excessive 
drinking, and presence of chronic liver disease. Serologic tests 330  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
   
Figure 1. Microscopic findings show moderate to severe inflammatory activity and intrahepatic cholestases without ductular destruction. 
(A) Hepatocyte ballooning and severe inflammation of the portal tracts with periportal fibrosis are noted (case 1, H&E×200). (B) 
Moderate inflammation with mild portal fibrosis is noted (case 2, H&E×200). (C) Intrahepatic cholestasis and severe lobular 
inflammation with periportal fibrosis are noted (case 3, H&E×200).
Table 1. Demographic data and clinical courses of the patients with cholestatic hepatitis A
Case 1 2 3
Age (yr) 40 35 42
Peak serum ALT (IU/L) 7,090 163 118
Peak serum total bilirubin (mg/dL) 23.5 31.79 31.5
Pre-prednisolone treatment serum ALT (IU/L) 158 59 35
Pre-prednisolone treatment serum total bilirubin (mg/dL) 19.8 27.97 31.5
Hospital days before administration of prednisolone (day) 28 30
* 43
†
Time to discharge after prednisolone use (day) 14 27 13
Time to decrease below the half level of pretreatment bilirubin (day) 13 23 8
Time to normalization of serum bilirubin (day) 55 82 60
* This includes admission periods of 20 days at a local hospital for symptomatic treatment.
† This includes admission periods of 25 days at a local hospital for symptomatic treatment.
showed negative responses to hepatitis B surface antigen 
(HBsAg), IgM antibody to hepatitis B cores antigen (IgM 
anti-HBc), hepatitis C antibody (HCV Ab), and IgM antibody to 
hepatitis E virus (IgM anti-HEV), while positive immune- 
reactivity to IgM antibody to hepatitis A virus (IgM anti-HAV) 
was observed, in all patients. On the basis of the history and the 
laboratory findings, acute viral hepatitis A was diagnosed. 
Supportive treatment with ursodeoxycholic acid, silymarin and 
intravenous fluid was done. However, sustained increase of 
serum bilirubin was observed. Possibility of obstructive jaundice 
was ruled out based on abdominal ultrasonography or CT scan. 
To exclude the possibility of infiltrative liver disease or small 
bile duct injury, liver biopsy was performed. On histopathologic 
examination, moderate to severe inflammatory cell infiltration 
was observed surrounding hepatic lobules and portal veins. 
Portal or periportal fibrosis and intracellular cholestasis were 
also found (Fig. 1). However there was no bile ductular lesion. 
Despite long-term conservative therapy, there was no significant 
improvement of the clinical features with persistence of 
hyperbilirubinemia. We started steroid therapy for the reversal of 
prolonged cholestasis. Possibility of the systemic infection other 
than viral hepatitis A was ruled out by absence of fever, 
leukocytosis, any abnormalities on chest X-ray, and pyuria. 
Prednisolone 30 mg was administered until serum bilirubin fell 
below the half level of baseline value. Thereafter, dose of steroid 
was tapered at intervals of two weeks and its administration was 
discontinued after 6-10 weeks (Table 1). 
The more detailed clinical information of the individual cases 
is described on the followings. 
Case 1
A 40-year-old man visited with complaints of general 
weakness for a week and jaundice for three days. His vital signs 
were stable, blood pressure of 140/100 mmHg, pulse rates of 94 
beats/minute, respiration rates of 20/minute and body temperature 
of 36℃ on the visit. He looked acutely ill with icteric sclerae. 
Abdominal examinations revealed tenderness on right upper 
quadrant area. Hepatosplenomegaly was not noted. Neither 
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Figure 2. Responses to steroids in individual subjects. Immediate 
declines of serum total bilirubin levels are noted after initiation 
of oral prednisolone. Black arrows indicate the time point when 
prednisolone was started.
pitting edema on extremities nor any neurologic abnormalities 
were found. On laboratory findings, complete blood count 
showed white blood cell (WBC) counts 4,370/mm
3, hemoglobin 
17.3 g/dL, platelets 101,000/mm
3  and his prothrombin time 
international normalized ratio (INR) was 1.64. On serum 
biochemistry, the patient showed total bilirubin 23.5 mg/dL, 
direct bilirubin 12.4 mg/dL, AST 5,558 IU/L, ALT 7,090 IU/L, 
ALP 75 IU/L and gamma-glutamyl transpeptidase (γ-GT) 456 
IU/L. Transient elastography measured the liver stiffness as high 
as 28.8 kPa. Finally acute viral hepatitis A was diagnosed and he 
was treated symptomatically. On week 4, although AST and ALT 
levels decreased to 173 IU/L and 152 IU/L, respectively, total 
bilirubin was still as high as 19.8 mg/dL with direct bilirubin of 
11.5 mg/dL. Also, cholestasis maintained, with complaints of 
severe pruritus, anorexia, and body weight loss. The patient 
started prednisolone at a dose of 30 mg/day. On the 13
th day of 
prednisolone administration, total and direct bilirubin decreased 
to 11.3 mg/dL and 6.1 mg/dL respectively with improvement of 
generalized symptoms, and he discharged. After 4 weeks 
following the administration of prednisolone, it was tapered off 
by 10 mg at intervals of two weeks. On the 8
th weeks, total 
bilirubin decreased to 1.7 mg/dL (Fig. 2). Liver stiffness on 
transient elastography became normalized to 3.6 kPa.
Case 2
A 35-year-old man diagnosed with acute hepatitis A was 
referred to our hospital after 2-weeks of hospitalization in the 
other hospital. On admission, his vital signs were stable. He 
looked acutely ill and icteric, but was in a clear mental status. On 
abdominal examination, a finger breadth of liver was palpable 
with mild tenderness in right upper quadrant area. No peripheral 
edema on extremities was found. On laboratory findings, complete 
blood count showed WBC counts 4,960/mm
3, hemoglobin 14.7 
g/dL, platelets 420,000/mm
3 and prothrombin time INR 0.94. On 
serum biochemistry, the patient showed total bilirubin 31.79 
mg/dL, direct bilirubin 17.3 mg/dL, AST 45 IU/L, ALT 53 IU/L, 
ALP 253 IU/L and γ-GT 309 IU/L. Transient elastography 
measured the liver stiffness as 14.1 kPa. Despite additional 
2-weeks of conservative therapy at our hospital, total and direct 
bilirubin were still elevated up to 27.97 mg/dL and 16.28 mg/dL, 
respectively. Jaundice and malaise persisted. Liver biopsy was 
done and prednisolone was initiated at a dose of 30 mg. On the 
23
rd day following administration of steroid, total and direct 
bilirubin declined to 13.2 mg/dL and 6.8 mg/dL. After 4 weeks of 
prednisolone therapy, it was tapered by 10 mg at intervals of two 
weeks and stopped after 12 weeks of administration. Total and 
direct bilirubin decreased to 1.09 mg/dL (Fig. 2). Liver stiffness 
declined to 7.0 kPa on transient elastography.
Case 3
A 42-year-old man, who had fever and nausea, received a 
diagnosis of acute hepatitis A at a local clinic. The patient was 
referred to us after 4-weeks of in-hospital treatment. His vital 
signs were stable. He was in a clear mental status, with icteric 
sclerae. Abdominal examination revealed mild right upper 
quadrant tenderness. Peripheral edema was not noted on 
extremities. On laboratory findings, complete blood count 
showed WBC counts 6,710/mm
3, hemoglobin 12.6 g/dL, 
platelets 434,000/mm
3 and his prothrombin time INR 1.08. On 
serum biochemistry, the patient showed total bilirubin 27.8 
mg/dL, direct bilirubin 14.8 mg/dL, AST 475 IU/L, ALT 104 
IU/L, ALP 121 IU/L and γ-GT 57 IU/L. Liver stiffness was 
measured as 23.4 kPa on transient elastography. Despite 
additional 3-weeks of conservative treatment, pruritus persisted, 
and appetite was decreased with significant body weight loss. On 
laboratory finding, total and direct bilirubin peaked up to 31.5 
mg/dL and 14.8 mg/dL, while AST and ALT were decreasing to 
59 IU/L and 30 IU/L, respectively. This led to biopsy of liver, 
after which 30 mg of prednisolone was administered. On 8
th day 
of prednisolone, total and direct bilirubin were rapidly 
decreasing to 13.99 mg/dL and 7.73 mg/dL, respectively. Liver 
stiffness declined to 20.1 kPa on 10
th day with the improvement 
of generalized symptoms. The patient discharged and prednisolone 
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clinic. Nine weeks after steroid treatment, total bilirubin 
decreased to 0.32 mg/dL (Fig. 2). 
DISCUSSION
Hepatitis A is a self-limited disease and is not associated with 
chronicity. Clinical presentations are more severe with increasing 
age, so adults are more frequently associated with prolonged 
jaundice compared to children. The genotype of the viral hepatitis 
A is also reported to affect the severity of the cholestasis.
5 
However, exact causes of prolonged cholestasis are unknown. 
Recently, the prevalence of its protective antibody has been 
decreasing in adolescents and adults in Korea. According to this, 
there is a tendency that mean age of patients with hepatitis A is 
gradually increasing. Therefore, it is expected that the number of 
patients who show severe clinical manifestation including 
prolonged cholestasis would increase.
1 Although presence of 
persistent cholestasis can still be managed symptomatically, this 
frequently lengthens hospital stay and causes medical expenses 
and socioeconomic loss. Therefore it is imperative that the 
methods be developed to improve clinical courses more 
promptly in patients with acute viral hepatitis A complicated by 
persistent uncontrolled cholestasis. Our report suggests that 
corticosteroid therapy is effective in these patients. 
Cholestasis can result from any defects in the step of the 
bilirubin metabolism; decreased uptake of bilirubin, impaired 
conjugation in the hepatocytes, disorders of bile excretion into 
biliary system, or obstruction of bile ducts may involve. 
Cholestasis accompanied by viral hepatitis A is mainly based on 
inflammatory responses. It is developed by the systemic and 
intrahepatic release of endotoxin (lipopolysaccharide) and 
pro-inflammatory cytokines including tumor necrosis factor-α 
(TNF-α) or interleukin-1 (IL-1).
6 It is therefore conceivable that 
cholestasis associated with this inflammatory process can be 
improved by the administration of steroids. It is known that 
multidrug resistance-associated protein 2 (mrp2), a transporter 
protein which is involved in excretion of the bilirubin outside the 
hepatocytes during the steps of bilirubin metabolism, is inhibited 
by TNF-α and IL-1.
7 Dexamethasone inhibits the synthesis of 
TNF-α and IL-1, and thereby prevents impairment of the 
function of mrp2 in the canaliculi of endotoxemic rats.
8 In 
addition, there are several glucocorticoid responsive elements on 
the promoter region of the mrp2 gene,
9 so dexamethasone 
induces the expression of mrp2 twice as much even in normal 
liver tissue and facilitates the metabolism of the bilirubin.
10 It 
was reported that a short course of corticosteroids therapy 
resulted in a rapid decline of serum bilirubin levels and relief of 
pruritus in approximately two-thirds of patients with acute 
cholestatic viral hepatitis.
11 However, there are also several 
contradictory reports that steroid therapy does not affect the 
clinical course or prognosis in patients with acute hepatitis with 
cholestasis. A prospective study conducted in 1981 with 77 acute 
viral hepatitis patients reported that there was no advantage with 
the use of corticosteroids early in the course of severe viral 
hepatitis.
12 It was also reported that cholestasis spontaneously 
resolves although corticosteroids may hasten the resolution, but 
it may predispose the patient to develop a relapse of the hepatitis 
in a study which dealt with atypical clinical manifestation of viral 
hepatitis in 1992.
13,14 Therefore, there are still controversies on 
the efficacy of steroid therapy. However, there might be variable 
responses depending on the time point of the administration of 
steroid, and there would be patient groups which might be 
clinically benefited from steroid treatment with prudent patient 
selection.
The clinical manifestations of acute cholestatic hepatitis A 
were presented recently in Korea. In 21 patients, mean value of 
the peak total bilirubin was 17.2 mg/dL (range, 11.4-44.9) and 
the mean time taken for bilirubin to be normalized was 93 days 
(range, 70-169). The study suggested that that severe cholestasis 
takes long duration to be improved by supportive care only, 
considering that most of the patients did not receive 
corticosteroid or other specific treatment.
4
In the current cases, despite the symptomatic treatment, all the 
patients suffered from pruritus, anorexia, and body weight loss. 
Besides, total bilirubin of 20 mg/dL or higher was not improved 
following approximately 4 weeks of conservative in-hospital 
treatment. Steroid was administered to alleviate their symptoms 
and shorten the length of hospital stay. Following steroid 
administration, the level of total bilirubin decreased to half of the 
pretreatment value within the mean of 14.7 days (range, 8-23), 
and the prompt response is considered to have reduced the period 
of hospital stay. However, the overall time period for full 
recovery might have not been shortened.
Recently, transient elastography is being used to estimate the 
stages of the hepatic fibrosis in a noninvasive manner. We 
performed transient elastography in our patients who were in 
acute phase of viral hepatitis, and it was measured as high as 23.2 
kPa in average. Comparing the mean value of 11.9-13.3 kPa of 
the peak liver stiffness in acute hepatitis A patients from the 
studies we reported previously,
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in the current case series showed significantly higher values. 
Considering that the histopathology showed at most portal or 
periportal fibrosis in these patients, this marked increase of liver 
stiffness is thought to have a relationship with the severity of 
intrahepatic necroinflammation or cholestasis. It was also 
previously reported that the increased liver stiffness found in 
patients with acute hepatitis would be related to the severity of 
the hepatocyte swelling resulted from necroinflammatory 
process.
17 However, there is no report demonstrated the increase 
of liver stiffness in acute viral hepatitis patients with corresponding 
histopathologic findings to our knowledge. In this sense, our 
clinical cases have a great value. Liver stiffness decreased in 
accordance with the stabilization of bilirubin level after 
treatment, which is a consistent finding with our previous 
reports.
15-16
There was no recurrence of hepatitis in all of our three 
patients. During the administration of prednisolone, there were 
no complications or adverse events in association with the 
immunosuppression. It would be mandatory, however, to 
evaluate the possibility of recurrence of hepatitis following the 
discontinuation of prednisolone with monitoring of the clinical 
courses.
Taken together, corticosteroid therapy is effective in improving 
clinical courses of the patients with cholestatic hepatitis A. 
Further placebo-controlled studies are also warranted to determine 
the efficacy of the steroid therapy in patients with cholestatic 
hepatitis who are refractory to a long-term conservative therapy. 
Acknowledgements
 
This study was supported by a grant from Ministry for Health, 
Welfare and Family Affairs, Republic of Korea (No. A050021).
REFERENCES
1. Jeong SH. Current status and vaccine indication for hepatitis A virus 
infection in Korea. Korean J Gastroenterol 2008;51:331-337.
2. Sjogren MH. Hepatitis A. In: Feldman M, Friedman LS, Brandt LJ, 
Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver 
Disease. Vol 2. 8th ed. Saunders, 2006:1639-1644.
3. Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. 
Intervirology 2010;53:15-19.
4. Jung KM, Cho YK, Cho JW, Park SH, Kim IH, Choi CS, et al. Clinical 
features of cholestatic hepatitis with acute viral hepatitis A in Chunbuk 
province of Korea: Multicenter experience[Abstract]. Korean J Hepatol 
2009;15(S3):S175.
5. Coppola N, Genovese D, Pisaturo M, Taffon S, Argentini C, Pasquale G, 
et al. Acute hepatitis with severe cholestasis and prolonged clinical 
course due to hepatitis A virus Ia and Ib coinfection. Clin Infect Dis 
2007;44:e73-77.
6. Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. J 
Gastroenterol Hepatol 1999;14:946-959.
7. Wolkoff AW. The hyperbilirubinemias. In: Fauci AS, Braunwald E, 
Kasper DL, Hauser SL, Longo DL, Jameson HL, eds. Harrison's 
principles of internal medicine. Vol II. 17th ed. Mc Graw Hill, 
2008:1927-1931.
8. Roelofsen H, Schoemaker B, Bakker C, Ottenhoff R, Jansen PL, 
Elferink RP. Impaired hepatocanalicular organic anion transport in 
endotoxemic rats. Am J Physiol 1995;269:G427-434.
9. Kauffmann HM, Schrenk D. Sequence analysis and functional 
characterization of the 5'-flanking region of the rat multidrug resistance 
protein 2 (mrp2) gene. Biochem Biophys Res Commun 1998;245:325-331.
10. Demeule M, Jodoin J, Beaulieu E, Brossard M, Beliveau R. 
Dexamethasone modulation of multidrug transporters in normal tissues. 
FEBS Lett 1999;442:208-214.
11. Sherlock S. Viral Hepatitis; General Features, Hepatitis A, Hepatitis E 
and Other Viruses. In: Sherlock S, Dooley J, eds. Diseases of the Liver 
and Biliary System. Oxford: Blackwell Scientific, 2002:272-276.
12. Ware AJ, Cuthbert JA, Shorey J, Gurian LE, Eigenbrodt EH, Combes B. 
A prospective trial of steroid therapy in severe viral hepatitis. The 
prognostic significance of bridging necrosis. Gastroenterology 1981; 
80:219-224.
13. Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 
1992;10 Supple 1:S18-20.
14. Dienstag J. Hepatitis A. In: Bircher J, McIntyre N, Rizzetto M, Rodes J, 
ed. Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford: Oxford 
University Press, 1999:870-875.
15. Seo YS, Lee KG, Jung ES, An H, Park S, Keum B, et al. Dynamic 
changes in liver stiffness during the course of acute hepatitis A. Scand J 
Gastroenterol 2010;45:449-456.
16. Kim JH, Yim HJ, Kim SY, Ahn JH, Jung YK, Joo MK, et al. Changes in 
liver stiffness after acute or chronic liver injury due to viral hepatitis- 
does fibrosis exist after recovery from acute viral hepatitis? Korean J 
Gastroenterol 2009;54:155-161.
17. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute 
viral hepatitis increases liver stiffness values measured by transient 
elastography. Hepatology 2008;47:380-384.